A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Conditions

• Brain Metastases
• Brain Metastases, Adult
• Lung Cancer
• Lung Cancer Metastatic
• Small Cell Lung Carcinoma
• Small-cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Stereotactic Radiosurgery — RADIATION
  All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
• Cerebrospinal fluid collection — PROCEDURE
  All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.

Study Details

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Key Dates

Start date

Jun 10, 2022

Status verified

Jun 2026

Primary completion

Jun 10, 2027

Completion

Jun 10, 2027

Study Design

Enrollment

62 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Participants with small cell lung cancer with brain metastases
  Participants may be newly diagnosed small cell lung cancer with brain metastases at initial staging, or can alternatively be patients who develop brain metastases on therapy or during surveillance of systemic disease.

Primary Outcome Measure

Overall survival [ Time Frame: 6 months ]

Central Contacts

• Luke Pike, MD
  201-775-7604
  [email protected]
• Brandon Imber, MD
  631-212-6346
  [email protected]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies

• Lung Cancer Biomarkers and Screening
  Recruiting · NYU Langone Health · New York, New York
• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
  PHASE2 · Recruiting · CivaTech Oncology · New York, New York
• WTC Chest CT Imaging Archive
  Enrolling By Invitation · Icahn School of Medicine at Mount Sinai · New York, New York